Applying molecular measurable residual disease testing in acute myeloid leukaemia
Details
Publication Year 2023-02,Volume 55,Issue #1,Page 1-7
Journal Title
Pathology
Publication Type
Review
Abstract
Molecular testing in acute myeloid leukaemia (AML) has continued to dramatically advance in recent years, facilitating the ability to detect residual disease at exponentially lower levels. With the advent of the recently updated ELN consensus recommendations, there is increasing complexity to ordering and interpreting measurable residual disease (MRD) assays in AML. We outline the technology itself in conjunction with the relevant testing timepoints, clinically significant thresholds and potential prognostic and therapeutic significance of MRD testing for the major molecular targets in AML. This practical overview should assist haematologists in incorporating molecular MRD assays routinely into their personalised AML clinical management.
Publisher
Elsevier
Keywords
Humans; *Leukemia, Myeloid, Acute/diagnosis/genetics; Prognosis; Neoplasm, Residual/diagnosis; Molecular Diagnostic Techniques; Flt3; Measurable residual disease; Npm1; acute myeloid leukaemia; clonal haematopoiesis
Department(s)
Clinical Haematology
PubMed ID
36503638
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-05-30 07:27:56
Last Modified: 2023-05-30 07:28:52

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙